Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases

Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases

CanProbe focuses on developing new radiopharmaceuticals to meet growing Canadian and global demand for advanced diagnostic and therapeutic molecular probes.

TORONTO, ON (June 22, 2011)-CanProbe, a unique, not-for-profit joint venture to advance the use of medical isotopes for diagnosing and treating cancer and other serious diseases, was announced today by the Centre for Probe Development and Commercialization (CPDC) and the University Health Network (UHN).